Investopedia
20 Aug 2026, 13:26 UTC · 10w ago
Moderna Stock Rockets Higher After Positive Cancer Vaccine Trial Data
Impact · against what's priced in
Moderna and Merck have achieved a major clinical milestone with their personalized skin-cancer vaccine meeting its primary Phase 3 endpoint. This late-stage success significantly increases the probability of commercialization and future revenue for both companies.
- MRNA+0.90
No priced-in read yet
- In context
The Phase 3 trial for intismeran met its primary goal of recurrence-free survival, representing a landmark shift toward commercial viability for Moderna's mRNA cancer platform.
Read from the article alone
Search tags
